Taylor Ingle
YOU?
Author Swipe
View article: Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine Open
Pharmacogenomics (PGx), studying the relationship between drug response and genetic makeup of an individual, is accelerating advances in precision medicine. The FDA includes PGx information in the labeling of approved drugs to better infor…
View article: Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Background Adverse Drug Reactions (ADRs) are of great public health concern. FDA-approved drug labeling summarizes ADRs of a drug product mainly in three sections, i.e., Boxed Warning (BW), Warnings and Precautions (WP), and Adverse Reacti…
View article: Additional file 5: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Additional file 5: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Table S5. 1164 selected SPL documents used in this study. (XLS 378 kb)
View article: Additional file 2: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Additional file 2: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Table S2. Drugs and PT distributions among MedDRA SOCs (XLS 33 kb)
View article: Additional file 4: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Additional file 4: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Table S4. MedDRA term extraction performance of Oracle Text Search (XLS 56 kb)
View article: Additional file 7: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Additional file 7: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Table S7. Detailed PT distributions among drug ATC categories (XLS 66 kb)
View article: Additional file 3: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Additional file 3: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Table S3. Enriched cluster among ATC N categories (XLS 40 kb)
View article: Additional file 6: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Additional file 6: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Table S6. Overview of ATC second-level involved drugs (XLS 42 kb)
View article: Additional file 1: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Additional file 1: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA Open
Table S1. The entire MedDRA PT corpus for Boxed Warning sections among selected 367 drugs; (XLS 62 kb)
View article: Evaluating the potential of gold, silver, and silica nanoparticles to saturate mononuclear phagocytic system tissues under repeat dosing conditions
Evaluating the potential of gold, silver, and silica nanoparticles to saturate mononuclear phagocytic system tissues under repeat dosing conditions Open
The clinical impact of these changes is unclear but suggests that the mononuclear phagocytic system is able to handle repeated doses of nanoparticles.
View article: Size- and coating-dependent cytotoxicity and genotoxicity of silver nanoparticles evaluated using <i>in vitro</i> standard assays
Size- and coating-dependent cytotoxicity and genotoxicity of silver nanoparticles evaluated using <i>in vitro</i> standard assays Open
The physicochemical characteristics of silver nanoparticles (AgNPs) may greatly alter their toxicological potential. To explore the effects of size and coating on the cytotoxicity and genotoxicity of AgNPs, six different types of AgNPs, ha…